Neoadjuvant chemotherapy in patients with stage IVB uterine serous carcinoma: a Turkish multicentric study

References

• Benito, V., et al., 2009. Pure papillary serous tumors of the endometrium: a clinicopathological analysis of 61 cases from a single institution. International Journal of Gynecologic Cancer, 19.
   PubMed Web of Science ®Google Scholar
• Bogani, G., et al., 2019. Neoadjuvant chemotherapy followed by interval debulking surgery for unresectable stage IVB Serous endometrial cancer. Tumori, 105 (1), 92–97.
   PubMed Web of Science ®Google Scholar
• Bokhman, J. V., 1983. Two pathogenetic types of endometrial carcinoma. Gynecologic Oncology, 15 (1), 10–17.
   PubMed Web of Science ®Google Scholar
• Boruta, D.M., II., et al., 2009. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecologic Oncology, 115 (1), 142–153.
   PubMed Web of Science ®Google Scholar
• DE Lange, N., et al., 2019. Neoadjuvant chemotherapy followed by surgery for advanced-stage endometrial cancer. Current Oncology, 26 (2), 226–232.
   Web of Science ®Google Scholar
• Eggemann, H., et al., 2016. Survival advantage of lymphadenectomy in endometrial cancer. Journal of Cancer Research and Clinical Oncology, 142 (5), 1051–1060.
   PubMed Web of Science ®Google Scholar
• Eto, T., et al., 2013. Status of treatment for the overall population of patients with stage IVb endometrial cancer, and evaluation of the role of preoperative chemotherapy: a retrospective multi-institutional study of 426 patients in Japan. Gynecologic Oncology, 131 (3), 574–580.
   PubMed Web of Science ®Google Scholar
• Fader, A.N., Santin, A.D., and Gehrig, P.A., 2013. Early stage uterine serous carcinoma: management updates and genomic advances. Gynecologic Oncology, 129 (1), 244–250.
   PubMed Web of Science ®Google Scholar
• Goldberg, H., et al., 2008. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN). Gynecologic Oncology, 108 (2), 298–305.
   PubMed Web of Science ®Google Scholar
• Hamilton, C.A., Kapp, D.S. and Chan, J.K. 2008. Clinical aspects of uterine papillary serous carcinoma. Current Opinion in Obstetrics & Gynecology, 20 (1), 26–33.
   PubMed Web of Science ®Google Scholar
• Hendrickson, M., et al., 1982. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. The American Journal of Surgical Pathology, 6 (2), 93–108.
   PubMed Web of Science ®Google Scholar
• Huang, A.B., et al., 2021. Neoadjuvant chemotherapy for advanced stage endometrial cancer: a systematic review. Gynecologic Oncology Reports, 38, 100887.
   PubMed Web of Science ®Google Scholar
• Kehoe, S., et al., 2015. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet (London, England), 386 (9990), 249–257.
   PubMed Web of Science ®Google Scholar
• Khouri, O. R., et al., 2019. Neoadjuvant chemotherapy in patients with advanced endometrial cancer. Cancer Chemotherapy and Pharmacology, 84 (2), 281–285.
   PubMed Web of Science ®Google Scholar
• Patsavas, K., et al., 2011. Optimal surgical debulking in uterine papillary serous carcinoma affects survival. Gynecologic Oncology, 121 (3), 581–585.
   PubMed Web of Science ®Google Scholar
• Rabinovich, A., 2016. Neo-adjuvant chemotherapy for advanced stage endometrial carcinoma: a glimmer of hope in select patients. Archives of Gynecology and Obstetrics, 293 (1), 47–53.
   PubMed Web of Science ®Google Scholar
• Schoenfeld, D.A., 1983. Sample-size formula for the proportional-hazards regression model. Biometrics, 39 (2), 499–503.
   PubMed Web of Science ®Google Scholar
• Siegel, R.L., Miller, K.D., and Jemal, A., 2020. Cancer statistics, 2020. CA: A Cancer Journal for Clinicians, 70 (1), 7–30.
   PubMed Web of Science ®Google Scholar
• Slomovitz, B.M., et al., 2003. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecologic Oncology, 91 (3), 463–469.
   PubMed Web of Science ®Google Scholar
• Tobias, C.J., et al., 2020. Association of neoadjuvant chemotherapy with overall survival in women with metastatic endometrial cancer. JAMA Network Open, 3 (12), e2028612–e2028612.
   Web of Science ®Google Scholar
• Todo, Y., et al., 2010. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. The Lancet, 375 (9721), 1165–1172.
   PubMed Web of Science ®Google Scholar
• Vandenput, I., et al., 2009. Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? British Journal of Cancer, 101 (2), 244–249.
   PubMed Web of Science ®Google Scholar
• Vergote, I., et al., 2010. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine, 363 (10), 943–953.
   PubMed Web of Science ®Google Scholar
• Wilkinson-Ryan, I., et al., 2015. Neoadjuvant chemotherapy versus primary cytoreductive surgery for stage IV uterine serous carcinoma. International Journal of Gynecologic Cancer, 25 (1), 63–68.
   PubMedGoogle Scholar
• Young, R., 2014. Monodermal teratomas and somatic-type tumours arising from a dermoid cyst. In: R.J. Kurman, M.L. Carcangiu, C.S. Herrington, R.H. Young, eds. WHO classification of tumours of female reproductive organs. USA: World Health Organization, 63–66.
   Google Scholar
• Zhong, X., et al., 2018. Prognostic factors of uterine serous carcinoma—a multicenter study. International Journal of Gynecologic Cancer, 28 (6), 1138–1144.
   Google Scholar